t
N4 Pharma plc announced on April 4, 2025, that it is posting a circular containing a Notice of General Meeting and Forms of Proxy to shareholders. This circular relates to the proposed Placing and Subscription, initially announced on April 1, 2025, and resolutions to be put to shareholders. The General Meeting is scheduled for April 22, 2025, at 11 a.m.
| Date | 4 Apr 2025 |
| Time | 07:08:13 |
| Category | AGMs and other meetings |
| ID | 6961D |
4 April 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Posting of Circular and Notice of General Meeting
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces that it is today posting a circular containing a Notice of General Meeting and Forms of Proxy to shareholders regarding the proposed Placing and Subscription, as announced on 1 April 2025, and the resolutions to be put to shareholders at the General Meeting.
The General Meeting will be held on 22 April 2025 at 11 a.m. at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.
The circular and Notice of General Meeting will shortly be available on the Company's website: https://www.n4pharma.com/investors/investor-information/
- Ends -
For more information please contact:
|
N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Engage with us directly at N4 Pharma Investor Hub
To find out more, visit |
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
|
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope |
Tel: +44 (0)20 3657 0050 |
|
Northstar Communications Limited Investor Relations Sarah Hollins |
Tel: +44 (0)113 730 3896
|
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set, and working towards first-in-human clinical data, to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.